Pipeline

TAC Product Candidate pipeline 1Q-2021 graph
click image to enlarge

HER2

Human epidermal growth factor receptor 2 (HER2) has been implicated in several aggressive cancers such as in about 62% of glioblastoma multiforme patients (1,2), a typically incurable brain tumor, and in about 20% of breast cancer patients (3,4). It is also expressed in several other cancers. Glioblastoma multiforme is expected to impact approximately 16,000 patients (5), and HER2 positive breast cancer is expected to impact approximately 54,000 patients (6), in the US in 2018.

BCMA and Multiple Myeloma

Survival of plasma cells is regulated by B cell maturation antigen (BCMA). Multiple myeloma is a plasma cell disorder that remains an incurable disease, despite recent therapeutic advances. Multiple myeloma is expected to impact approximately 31,000 patients in the US in 2018 (7).